Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
November 09 2023 - 8:15AM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the
“Company”), a clinical-stage pharmaceutical company focused on
developing the next generation of chemotherapeutic drugs to improve
the efficacy and safety for patients suffering from cancer,
announces that Dr. David Young, President of Research and
Development, will present at the 20th Orphan Drugs and Rare
Diseases Global Congress 2023 Americas.
The conference is being held on November 16 –
17, 2023 at the Revere Hotel Boston Common, 200 Stuart Street,
Boston, MA 02116.
Presentation Date: Thursday, November
16
Time: 2:40pm ET
Dr. Young will be available for one-on-one
meetings throughout the conference.
For more information about the conference, click
below:https://www.paradigmglobalevents.com/events/21st-orphan-drugs-rare-diseases-global-congress-2023-americas/
About Processa Pharmaceuticals,
Inc.
Processa is a clinical stage pharmaceutical
company focused on developing the Next Generation Chemotherapy
drugs to improve the safety and efficacy of cancer treatment. By
combining Processa’s novel oncology pipeline with proven
cancer-killing active molecules and the Processa Regulatory Science
Approach as well as experience in defining Optimal Dosage Regimens
for FDA approvals, Processa not only will be providing better
therapy options to cancer patients but also increase the
probability of FDA approval for its Next Generation Chemotherapy
drugs. Processa’s NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the
metabolism and/or distribution of drugs while maintaining the
existing mechanisms of killing the cancer cells. Our approach to
drug development is based on more than 30 years of drug development
expertise to efficiently design and conduct clinical trials that
demonstrate a positive benefit/risk relationship. Using its proven
Regulatory Science Approach, we have experience defining the
Optimal Dosage Regimen using the principles of the FDA’s Project
Optimus Oncology initiative. The advantages of Processa’s Next
Generation Chemotherapy drugs are expected to include fewer
patients experiencing side effects that lead to dose
discontinuation; more significant cancer response; and a greater
number of patients who will benefit from each Next Generation
Chemotherapy drug. Currently in our pipeline are three Next
Generation Chemotherapy drugs: Next Generation Capecitabine
(PCS6422 and capecitabine to treat metastatic colorectal,
gastrointestinal, breast, pancreatic, and other cancers), Next
Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian,
breast, and other cancers), and Next Generation Irinotecan (PCS11T
to treat lung, colorectal, gastrointestinal, pancreatic, and other
cancers).
For more information, visit our website
at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More
Information:Investors:Bret ShapiroCORE
IRir@processapharma.com
Company Contact:Patrick Lin(925)
683-3218plin@processapharma.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Oct 2023 to Oct 2024